WO2006127978A3 - Compositions and methods for the treatment of cancer - Google Patents

Compositions and methods for the treatment of cancer Download PDF

Info

Publication number
WO2006127978A3
WO2006127978A3 PCT/US2006/020390 US2006020390W WO2006127978A3 WO 2006127978 A3 WO2006127978 A3 WO 2006127978A3 US 2006020390 W US2006020390 W US 2006020390W WO 2006127978 A3 WO2006127978 A3 WO 2006127978A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
methods
compositions
useful
Prior art date
Application number
PCT/US2006/020390
Other languages
French (fr)
Other versions
WO2006127978A2 (en
Inventor
Andrea Alan D D
Toshiyasu Taniguchi
Original Assignee
Dana Farber Cancer Inst Inc
Andrea Alan D D
Toshiyasu Taniguchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Andrea Alan D D, Toshiyasu Taniguchi filed Critical Dana Farber Cancer Inst Inc
Priority to EP06784482A priority Critical patent/EP1904088A4/en
Priority to CA002609751A priority patent/CA2609751A1/en
Priority to JP2008513749A priority patent/JP2008545965A/en
Priority to AU2006249807A priority patent/AU2006249807A1/en
Publication of WO2006127978A2 publication Critical patent/WO2006127978A2/en
Publication of WO2006127978A3 publication Critical patent/WO2006127978A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Disclosed herein are methods and compositions for the treatment of cancer. In particular, the present invention discloses inhibitors of the Fanconi anemia pathway and methods using same. Such inhibitors are useful in inhibiting DNA damage repair and can be useful, for example, in the treatment of cancer.
PCT/US2006/020390 2005-05-24 2006-05-24 Compositions and methods for the treatment of cancer WO2006127978A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP06784482A EP1904088A4 (en) 2005-05-24 2006-05-24 Compositions and methods for the treatment of cancer
CA002609751A CA2609751A1 (en) 2005-05-24 2006-05-24 Compositions and methods for the treatment of cancer
JP2008513749A JP2008545965A (en) 2005-05-24 2006-05-24 Compositions and methods for the treatment of cancer
AU2006249807A AU2006249807A1 (en) 2005-05-24 2006-05-24 Compositions and methods for the treatment of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68413605P 2005-05-24 2005-05-24
US60/684,136 2005-05-24

Publications (2)

Publication Number Publication Date
WO2006127978A2 WO2006127978A2 (en) 2006-11-30
WO2006127978A3 true WO2006127978A3 (en) 2009-04-30

Family

ID=37452873

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/020390 WO2006127978A2 (en) 2005-05-24 2006-05-24 Compositions and methods for the treatment of cancer

Country Status (5)

Country Link
EP (1) EP1904088A4 (en)
JP (1) JP2008545965A (en)
AU (1) AU2006249807A1 (en)
CA (1) CA2609751A1 (en)
WO (1) WO2006127978A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090062196A1 (en) * 2006-10-20 2009-03-05 D Andrea Alan Compositions and methods of treating cancer
JP2010521670A (en) * 2007-03-12 2010-06-24 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド Use of FANCI and drugs that modulate FANCI in the prognosis, in diagnosis, and in the treatment of cancer
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
US9821008B2 (en) 2013-11-25 2017-11-21 The University Of Toledo Inhibitors of ERCC1-XPF and methods of using the same
US20180085377A1 (en) * 2015-04-22 2018-03-29 Syn-Nat Products Enterprise LLC Co-crystal composition and its pharmaceutical use
CA3028134A1 (en) 2016-06-17 2017-12-21 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+ cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030093819A1 (en) * 2000-11-03 2003-05-15 D'andrea Alan D. Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
US20030188326A1 (en) * 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1728077A4 (en) * 2004-01-30 2008-11-05 Dana Farber Cancer Inst Inc Method for determination and quantification of radiation or genotoxin exposure

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030093819A1 (en) * 2000-11-03 2003-05-15 D'andrea Alan D. Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
US20030188326A1 (en) * 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Blood.", vol. 96, November 2000, 42ND ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, SAN FRANCISCO, CA, USA, article TANIGUCHI ET AL.: "DNA damage-induced association of the Fanconi Anemia protein, FANCD2, with BRCA1 nuclear foci.", pages: 559A, XP001119144 *
"Blood.", vol. 96, November 2000, 42ND MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, SAN FRANCISCO, CA, USA, ISSN: 0006-4971, article HAINING ET AL.: "Rapid assessment of Fanconi pathway function: A new diagnostic approach to Fanconi Anemia", pages: 229A, XP008125107 *
DIGWEED ET AL.: "Attenuation of the formation of DNA-repair foci containing RAD51 in Fancon anaemia.", CARCINOGENESIS, vol. 23, no. 7, 2002, pages 1121 - 1126, XP008125093 *
GARCIA-HIGUERA ET AL.: "Interaction of the Fanconi Anemia proteins and BRCA1 in a common pathway.", MOLECULAR CELL., vol. 7, February 2001 (2001-02-01), pages 249 - 262, XP003005795 *
GREGORY ET AL.: "Regulation of the Fanconi anemia pathway by monoubiquination", SEMINARS IN CANCER BIOLOGY, vol. 13, 2003, pages 77 - 82, XP008125091 *
HOLZEL ET AL.: "FANCD2 protein is expressed in proliferating cells of human tissues that are cancer-prone in Fanconi anaemia", J.OF PATHOLOGY, vol. 201, 2003, pages 198 - 203, XP008125090 *
LENSCH ET AL.: "Acquired FANCA dysfunction and cytogenic instability in adult acute myelogenous leukemia.", BLOOD., vol. 102, no. 1, July 2003 (2003-07-01), pages 7 - 16, XP008125092 *
See also references of EP1904088A4 *
SHIMAMURA ET AL.: "A novel diagnostic screen for defects in the Fanconi anemia pathway.", BLOOD., vol. 100, no. 13, December 2002 (2002-12-01), pages 4649 - 4654, XP008125079 *

Also Published As

Publication number Publication date
CA2609751A1 (en) 2006-11-30
EP1904088A4 (en) 2010-03-31
EP1904088A2 (en) 2008-04-02
JP2008545965A (en) 2008-12-18
AU2006249807A1 (en) 2006-11-30
WO2006127978A2 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
EP1863507A4 (en) Compositions and methods for treating acne
WO2008013589A3 (en) Treatment of ras-expressing tumors
WO2008031041A3 (en) Melanoma gene signature
WO2007002204A3 (en) Pyrosequencing methods and related compostions
PL2079677T3 (en) Macromolecular amine-phenolic antioxidant compositions, process technology thereof, and uses thereof
EP1959929A4 (en) Compositions and methods for treating dermatological conditions
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
WO2007073553A3 (en) Block copolymer particles
WO2007016591A3 (en) Compositions and methods for monitoring and altering protein folding and solubility
WO2006072612A3 (en) Triazolophthalazines as pde2- inhibitors
IL186127A (en) Pharmaceutical compositions for treating depression and methods for preparing the same
WO2007016674A3 (en) 2-aminoaryl pyridines as protein kinases inhibitors
IL188263A0 (en) Method and compositions for enhancing vascular access
WO2006036817A3 (en) Fungal variants and uses thereof
WO2008088922A3 (en) Prevention of hydrogel viscosity loss
WO2008060795A3 (en) Antimicrobial articles and method of manufacture
WO2007140205A3 (en) Methods of treating fibrosis
EP1855662A4 (en) Methods and compositions for treating cancer
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
WO2007067784A3 (en) Liposomal compositions
WO2006127978A3 (en) Compositions and methods for the treatment of cancer
WO2006078998A3 (en) Methods and compositions for decreasing saliva production
WO2006098998A3 (en) Methods and compositions for modulating vascular integrity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006249807

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2008513749

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2609751

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006784482

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU